An Australian perspective on clinical, economic and regulatory considerations in emerging nanoparticle therapies for infections.

Muir, BW; Payne, JAE; Martin, JH; O' Shea, R; Rajesh, S; Blackman, LD; Shen, H-H; Heazlewood, C; Bansal, V; Morgan, B

An Australian perspective on clinical, economic and regulatory considerations in emerging nanoparticle therapies for infections.

Muir, BW Payne, JAE Martin, JH O' Shea, R Rajesh, S Blackman, LD Shen, H-H Heazlewood, C Bansal, V Morgan, B

Permalink

Publisher:: Springer Nature
Publication Type:: Journal Article
Citation:: NPJ Antimicrob Resist, 2025, 3, (1), pp. 9
Issue Date:: 2025-02-18

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Accepted versionAdobe PDF (807.59 kB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Muir, BW
dc.contributor.author	Payne, JAE
dc.contributor.author	Martin, JH
dc.contributor.author	O' Shea, R
dc.contributor.author	Rajesh, S
dc.contributor.author	Blackman, LD
dc.contributor.author	Shen, H-H
dc.contributor.author	Heazlewood, C
dc.contributor.author	Bansal, V
dc.contributor.author	Morgan, B https://orcid.org/0000-0001-5318-1675
dc.date.accessioned	2026-02-03T08:10:51Z
dc.date.available	2024-11-28
dc.date.available	2026-02-03T08:10:51Z
dc.date.issued	2025-02-18
dc.identifier.citation	NPJ Antimicrob Resist, 2025, 3, (1), pp. 9
dc.identifier.issn	2731-8745
dc.identifier.issn	2731-8745
dc.identifier.uri	http://hdl.handle.net/10453/192750
dc.description.abstract	Antimicrobial resistance (AMR) poses a growing global health threat. Nanomedicine, combined with drug repurposing, may help extend the effective lifespan of current and new antimicrobials. This review, presents an Australian perspective on nanotechnology-based therapies, highlighting scientific and clinical challenges. Early consideration of the potential barriers to market access may help to accelerate research translation, regulatory approval and patient access to nano-antimicrobial (NAM) drugs for resistant pathogens, not only in Australia, but globally.
dc.format	Electronic
dc.language	eng
dc.publisher	Springer Nature
dc.relation.ispartof	NPJ Antimicrob Resist
dc.relation.isbasedon	10.1038/s44259-024-00070-3
dc.rights	info:eu-repo/semantics/openAccess
dc.title	An Australian perspective on clinical, economic and regulatory considerations in emerging nanoparticle therapies for infections.
dc.type	Journal Article
utslib.citation.volume	3
utslib.location.activity	England
pubs.organisational-group	University of Technology Sydney
pubs.organisational-group	University of Technology Sydney/Faculty of Science
utslib.copyright.status	open_access	*
dc.rights.license	This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/
dc.date.updated	2026-02-03T08:10:49Z
pubs.issue	1
pubs.publication-status	Published online
pubs.volume	3
utslib.citation.issue	1

Abstract:

Antimicrobial resistance (AMR) poses a growing global health threat. Nanomedicine, combined with drug repurposing, may help extend the effective lifespan of current and new antimicrobials. This review, presents an Australian perspective on nanotechnology-based therapies, highlighting scientific and clinical challenges. Early consideration of the potential barriers to market access may help to accelerate research translation, regulatory approval and patient access to nano-antimicrobial (NAM) drugs for resistant pathogens, not only in Australia, but globally.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/192750